These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 28992430)

  • 21. The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectations.
    Gintant G; Traebert M
    Expert Opin Drug Discov; 2020 Jun; 15(6):719-729. PubMed ID: 32129680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
    Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
    Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.
    Sachinidis A
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
    Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
    Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.
    Tzatzalos E; Abilez OJ; Shukla P; Wu JC
    Adv Drug Deliv Rev; 2016 Jan; 96():234-244. PubMed ID: 26428619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
    Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
    Mozneb M; Jenkins A; Sances S; Pohlman S; Workman MJ; West D; Ondatje B; El-Ghazawi K; Woodbury A; Garcia VJ; Patel S; Arzt M; Dezem F; Laperle AH; Moser VA; Ho R; Yucer N; Plummer J; Barrett RJ; Svendsen CN; Sharma A
    Lab Chip; 2024 Feb; 24(4):869-881. PubMed ID: 38252454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
    Narkar A; Willard JM; Blinova K
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of local anesthetic-induced heart toxicity using human induced pluripotent stem cell-derived cardiomyocytes.
    Jiang T; Ma C; Wang Z; Miao Y
    Mol Cell Probes; 2024 Aug; 76():101965. PubMed ID: 38823509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating nonlinear analysis and machine learning for human induced pluripotent stem cell-based drug cardiotoxicity testing.
    Kowalczewski A; Sakolish C; Hoang P; Liu X; Jacquir S; Rusyn I; Ma Z
    J Tissue Eng Regen Med; 2022 Aug; 16(8):732-743. PubMed ID: 35621199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
    Rajasingh S; Isai DG; Samanta S; Zhou ZG; Dawn B; Kinsey WH; Czirok A; Rajasingh J
    Acta Pharmacol Sin; 2018 Oct; 39(10):1590-1603. PubMed ID: 29620051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.
    Abi-Gerges N; Miller PE; Ghetti A
    Curr Pharm Biotechnol; 2020; 21(9):787-806. PubMed ID: 31820682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human engineered heart tissue as a model system for drug testing.
    Eder A; Vollert I; Hansen A; Eschenhagen T
    Adv Drug Deliv Rev; 2016 Jan; 96():214-24. PubMed ID: 26026976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
    Maddah M; Mandegar MA; Dame K; Grafton F; Loewke K; Ribeiro AJS
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106895. PubMed ID: 32629158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes.
    Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
    J Toxicol Sci; 2021; 46(8):359-369. PubMed ID: 34334557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes].
    Yanagida S; Kanda Y
    Yakugaku Zasshi; 2024; 144(3):265-271. PubMed ID: 38432935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.